Lucidophilic Ackermann strain and application of Lucidophilic Ackermann strain

Abstract

The invention relates to the field of microorganisms, in particular to a mucophilic protein Ackermann strain and application thereof, and the preservation number of the mucophilic protein Ackermann strain is CCTCC (China Center for Type Culture Collection) NO: M 20241304. The Ackermania muciniphila AKK-86 disclosed by the invention has good effects of promoting iron absorption, improving iron metabolism and relieving intestinal inflammation at the same time. In addition, the Ackermansiella muciniphila can also promote the generation of GLP-1, and has the potential of application in the aspects of reducing blood sugar and losing weight products.

Description

Technical Field

[0001] The invention relates to the field of microorganisms, in particular to an Akkermansia muciniphila strain and application thereof. Background Art

[0002] Iron deficiency anemia (IDA), characterized by hemoglobin levels <10.0 g / dL, is associated with learning problems, frailty, and an increased risk of comorbidities, such as infection and death. According to the World Health Organization, children, adolescents, and young women and pregnant women are most susceptible to this disease. Iron deficiency can also adversely affect the functional regulation of specific immune systems, such as immunocompetent cells and their cytokines, which in turn affects the level of inflammation.

[0003] Fortifying foods with iron has been a common practice in recent decades. However, the greatest concern is the physiological availability of the iron ingested in fortified foods. Foods that act as iron carriers must take into account their synergistic effects with iron complexes to absorb and increase availability. The main foods used for iron fortification are cereals and dairy products. Cereals, flours, and derived foods are not ideal carriers due to their high phytic acid content, which leads to reduced iron absorption. Oral iron supplements can also help improve the incidence of IDA, but commonly used iron supplements such as ferrous sulfate, sodium ethylenediaminetetraferrate, and bisglycinate ferrous chelate affect the taste of food. Moreover, excessive iron intake, if not absorbed, will be deposited in the colon to produce free radicals, causing intestinal inflammation, destroying the intestinal microbiota, and leading to changes in the ratio of protective bacteria and pathogenic bacteria.

[0004] Probiotics have been widely recognized by consumers due to their safety and probiotic properties. Using probiotics as a carrier to treat IDA together with iron supplements can improve the bioavailability of iron supplements and enhance the therapeutic effect, becoming an effective method.

[0005] In addition, probiotics can regulate various metabolic functions, including intestinal barrier homeostasis, glucose homeostasis, and energy absorption. A large number of studies have shown that supplementing with live or pasteurized Akkermansia muciniphila can improve diabetes, improve intestinal barrier function, and thus improve systemic metabolic conditions. GLP-1 can stimulate the secretion of insulin and promote the reduction of blood sugar. Secondly, GLP-1 can inhibit the secretion of glucagon, thereby reducing the liver's production of glucose. Summary of the invention

[0006] In view of the above-mentioned shortcomings of the prior art, an object of the present invention is to provide an Akkermansia muciniphila strain and application thereof, so as to solve the problems in the prior art.

[0007] To achieve the above-mentioned object and other related objects, the present invention provides an Akkermansia muciniphila AKK-86 strain, with a deposit number of CCTCC NO:M 20241304.

[0008] The present invention also provides a bacterial agent, which contains the Akkermansia muciniphila AKK-86, i.e., live bacteria and / or its postbiotics.

[0009] The present invention also provides a method for preparing the bacterial agent, comprising inoculating the pure strain of Akkermansia muciniphila AKK-86 into a culture medium for cultivation, centrifuging after the cultivation, collecting the precipitate, or adding a protective agent and then freeze-drying to obtain the bacterial agent.

[0010] The present invention also provides use of Akkermansia muciniphila or its postbiotics in preparing products promoting iron absorption, iron supplement products, blood sugar lowering products, diabetes prevention products, diabetes treatment products, weight loss products or products improving intestinal inflammation.

[0011] The present invention also provides an iron supplement product, which comprises an iron supplement and Akkermansia muciniphila or a postbiotic thereof.

[0012] As described above, the Akkermansia muciniphila strain and its application of the present invention have the following beneficial effects: the Akkermansia muciniphila AKK-86 of the present invention has good effects of promoting iron absorption, improving iron metabolism, and relieving intestinal inflammation. In addition, the Akkermansia muciniphila of the present invention can also promote the production of GLP-1, and has the potential for application in reducing fasting blood sugar and weight loss products. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figure 1 Shown is the mass spectrum of time-of-flight mass spectrometry identification of Akkermansia muciniphila.

[0014] Figure 2 Shown are the effects of Akkermansia muciniphila and its postbiotics on ferritin production in Caco-2 cells.

[0015] Figure 3 Shown are the effects of Akkermansia muciniphila and its postbiotics on the production of proinflammatory cytokines by macrophages.

[0016] Figure 4 Shown is the effect of Akkermansia muciniphila and its postbiotics on serum iron levels in mice.

[0017] Figure 5 Effects of Akkermansia muciniphila and its postbiotics on pro-inflammatory and anti-inflammatory factors in mouse serum

[0018] Figure 6 Shown is the effect of Akkermansia muciniphila and its postbiotics on GLP-1 production in NCI-H716 cells

[0019] Figure 7 Shown is the effect of Akkermansia muciniphila and its postbiotics on body weight in mice

[0020] Figure 8 The figure shows the effect of Akkermansia muciniphila and its postbiotics on serum fasting blood glucose and serum GLP-1 in mice. ** indicates that the experimental group is compared with the control group p < 0.01; *** indicates that the experimental group is compared with the control group p < 0.001.

[0021] Different superscript letters (a, b, c, d) indicate p < 0.05; DETAILED DESCRIPTION

[0022] The present invention firstly conducts a large number of screenings through an in vitro test for promoting ferritin synthesis in Caco-2 cells, and finds some strains that can promote the synthesis of ferritin in Caco-2 cells, among which Akkermansia muciniphila AKK-86 has the best effect.

[0023] Based on this, the present invention provides a strain of Akkermansia muciniphila, which is deposited in the China Center for Type Culture Collection (CCTCC), the strain name is Akkermansia muciniphila AKK-86, the deposit number is CCTCC NO:M 20241304, the deposit date is June 19, 2024, and the deposit address is Wuhan University, Wuhan, China.

[0024] The Akkermansia muciniphila AKK-86 increased iron absorption by 428% compared to the group to which Akkermansia muciniphila AKK-86 was not added.

[0025] The improved rate of iron absorption is obtained by the following method:

[0026] The final concentration of 50 μM FeCl3 and Caco-2 cells were used as the control group, and the experimental group was supplemented with 2*10 8 cfu / mL of live Akkermansia muciniphila AKK-86, the experimental group and the control group were co-cultured for 24 hours, and the ferritin in the Caco-2 cells of the two groups was detected after the culture, and the improvement rate was calculated using the following formula 1):

[0027] Improvement rate = (A0–A1) / A1×100%1)

[0028] Wherein: A0 is the intracellular ferritin concentration of the experimental group; A1 is the intracellular ferritin concentration of the control group.

[0029] The present invention also provides a bacterial agent, which contains the Akkermansia muciniphila AKK-86, i.e., live bacteria and / or its postbiotics.

[0030] Postbiotics refer to preparations of non-living microorganisms and / or their components that are beneficial to the health of the host. Postbiotics include inactivated microbial cells or cell components, such as dead cells, cell walls, cell membrane lipids, peptidoglycans, or metabolites (such as short-chain fatty acids, vitamins, or bacteriocins) that have been inactivated (e.g., pasteurized).

[0031] The bacterial agent is a liquid bacterial agent or a solid bacterial agent.

[0032] In certain embodiments of the present invention, the bacterial agent includes 2*10 8 cfu / mL or cfu / g or above, or 2*10 8 TFU / mL or TFU / g or above of Akkermansia muciniphila AKK-86 or its equivalent postbiotics. CFU refers to colony forming unit, which is used to measure viable bacteria, and TFU is the total bacterial count, including dead and live bacteria.

[0033] The present invention also provides a method for preparing the bacterial agent, comprising the following steps: inoculating a pure strain of Akkermansia muciniphila AKK-86 into a culture medium for culturing, centrifuging after the culturing, collecting the precipitate, or adding a protective agent and then freeze-drying to obtain the bacterial agent.

[0034] In certain embodiments of the present invention, based on the total volume of the culture medium, the formula of the culture medium is 9-11 g / L tryptone, 16-19 g / L beef heart extract powder, 4-6 g / L sodium chloride, 1-3 g / L glucose, 1-4 g / L disodium hydrogen phosphate, and 4-6 g / L mucin.

[0035] Preferably, based on the total volume of the culture medium, the formula of the culture medium is: 10 g / L tryptone, 17.5 g / L beef heart extract powder, 5 g / L sodium chloride, 2 g / L glucose, 2.5 g / L disodium hydrogen phosphate, and 5 g / L mucin.

[0036] In certain embodiments of the present invention, the culture temperature is 30-38° C. Specifically, the culture temperature is, for example, 30-33° C., 33-35° C., or 35-38° C.

[0037] In certain embodiments of the present invention, the culture method is anaerobic culture, and the culture gas ratio is, for example, 85-94% N2, 5% H2, and 1-10% CO2.

[0038] In certain embodiments of the present invention, the method further comprises pasteurizing the collected bacterial liquid to obtain a bacterial agent containing the postbiotics of Akkermansia muciniphila AKK-86.

[0039] The postbiotics obtained after inactivation of Akkermansia muciniphila AKK-86 have an effect comparable to that of live bacteria.

[0040] The protective agent is not specifically limited, for example, skim milk powder, oligoxylose, trehalose, sodium glutamate, soluble starch, VC sodium salt, etc.

[0041] The present invention also provides use of Akkermansia muciniphila or its postbiotics in preparing products promoting iron absorption, iron supplement products, blood sugar lowering products, diabetes prevention products, diabetes treatment products, weight loss products or products improving intestinal inflammation.

[0042] In certain embodiments of the present invention, the Akkermansia muciniphila is Akkermansia muciniphila AKK-86.

[0043] The iron absorption promoting product has a higher iron absorption rate than the product without adding Akkermansia muciniphila or its postbiotics.

[0044] The blood sugar lowering product, diabetes prevention product, diabetes treatment product or weight loss product can promote GLP-1 secretion.

[0045] The present invention also provides an iron supplement product, which comprises an iron supplement and Akkermansia muciniphila or a postbiotic thereof.

[0046] The iron supplement is selected from any one or more of the following: ferrous sulfate, sodium ethylenediaminetetraferric, bisglycinate ferrous chelate, iron dextran, ferrous fumarate, polysaccharide iron complex, and ferrous succinate.

[0047] The Akkermansia muciniphila is Akkermansia muciniphila AKK-86.

[0048] The iron supplement product can improve iron absorption and enhance iron bioavailability.

[0049] The iron supplement product is food, health product or medicine.

[0050] The iron supplement product also includes a carrier or auxiliary material acceptable in food, health care products or medicines.

[0051] "Foodally, nutraceutically or pharmaceutically acceptable" means that the drugs do not produce adverse, allergic or other untoward reactions when properly administered to animals or humans.

[0052] "Carriers or excipients acceptable for food, health products or medicines" should be compatible with the active ingredient, that is, they can be mixed with it without significantly reducing the effect of the drug under normal circumstances. Specific examples of some substances that can be used as carriers or excipients are sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium methylcellulose, ethyl cellulose and methyl cellulose; tragacanth powder; malt; gelatin; talc; solid lubricants, such as stearic acid and magnesium stearate; calcium sulfate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and cocoa butter; polyols, such as propylene glycol, glycerol, sorbitol, mannitol and polyethylene glycol; alginic acid; emulsifiers, such as Tween; wetting agents, such as sodium lauryl sulfate; colorants; flavorings; tablets, stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic saline solution; and phosphate buffer, etc. These materials are used as needed to aid in the stability of the formulation or to help increase the activity or its bioavailability or to produce an acceptable taste or flavor in the case of oral administration.

[0053] The dosage form of the iron supplement product is not specifically limited, and may be, for example, an oral liquid, a lyophilized powder, a capsule, a tablet, a granule or a soft candy.

[0054] The following describes the embodiments of the present invention through specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention.

[0055] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing the specific embodiments rather than for limiting the scope of protection of the present invention; in the present specification and claims, unless otherwise expressly stated herein, the singular forms "a", "an" and "the" include plural forms.

[0056] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, the two endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any methods, equipment, and materials of the prior art similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention can also be used to realize the present invention.

[0057] Example 1 Isolation and identification of Akkermansia muciniphila

[0058] Take fresh feces from a healthy 6-year-old child, scoop a small amount with a sterile sampling spoon and put it in 5 mL of Green's solution. After sampling, immediately transfer the sample to an anaerobic box (gas environment: 80% N2, 10% H2, 10% CO2) and dilute the sample to 10 in a 1:10 dilution method. -10 . Take 0.1mL of each gradient dilution and apply it to the culture medium with mucin (5g / L) as the sole carbon source, and culture it anaerobically for 5 days. After a single colony grows, scrape a small amount of the single colony and expand it in the culture medium containing mucin. After culturing until it becomes obviously turbid, store it in a cryopreservation tube. The remaining single colony is used for time-of-flight mass spectrometry for identification. The mass spectrum of time-of-flight mass spectrometry identification is shown in Figure 1 (Rating explanation: [9.5, 10.0] species level confidence, possible subspecies; [9.0, 9.5) species level confidence; [6.0, 9.0) genus level confidence; [0.0, 6.0) unconfident). After the identification is completed, the cryopreserved tubes obtained by expanding the single colony identified as Akkermansia muciniphila are retained, and the other cryopreserved tubes are discarded.

[0059] Example 2 Effects of live Akkermansia muciniphila and its postbiotics on ferritin production in Caco-2 cells

[0060] The relative iron bioavailability between samples was measured using the Caco-2 cell bioassay established by Glahn R et al. This model uses the Caco-2 cell ferritin form as a marker of iron absorption. In Caco-2 cells, ferritin is an intracellular iron storage protein, and its content is proportional to the amount of cellular iron absorbed. By measuring the ferritin content in Caco-2 cells, iron bioavailability can be indirectly assessed.

[0061] The CaCo-2 cell group was used as the blank group. FeCl3 with a final concentration of 50 μM was used as an iron supplement and co-cultured with Caco-2 cells for 24 h. The FeCl3 group was used as the control group. The experimental group was added with 2*10 8 cfu / mL of live Akkermansia muciniphila (AKK), live Lactobacillus rhamnosus (LR), live Lactobacillus casei (LC) or their respective equivalent postbiotics.

[0062] Ferritin test results Figure 2 As shown in the figure, the ferritin content in the Fe+AKK live bacteria group and the Fe+AKK postbiotic group was significantly different from that in the control group, and was much higher than that in the live bacteria and postbiotic groups of Lactobacillus rhamnosus (LR) and Lactobacillus casei (LC). This indicates that live Akkermansia muciniphila and postbiotics have a good effect in promoting iron absorption.

[0063] Example 3 Effects of live Akkermansia muciniphila and its postbiotics on the production of pro-inflammatory factors by macrophages RAW 264.7

[0064] RAW 264.7 macrophages were cultured at 50,000 cells / cm 2 The cells were inoculated and cultured in RPMI medium for 24 h, and then cultured in groups according to Example 1. TNF-α and IL-6 were detected after 3 h of incubation according to the instructions of the ELISA kit (eBioscience Ltd., Hatfield, UK).

[0065] The results are as follows Figure 3 As shown in the figure, compared with the control group, the addition of live Akkermansia muciniphila or postbiotics decreased the levels of TNF-α and IL-6, and was extremely significant. This indicates that live Akkermansia muciniphila or its postbiotics can inhibit the production of pro-inflammatory factors and relieve inflammation.

[0066] Example 4 Effects of Akkermansia muciniphila and its postbiotics on iron absorption in mice

[0067] The experiment used 40 3-week-old ICR mice, alternating darkness and light every 12 hours, and the ambient temperature was 22±1℃. Intervention began after one week of adaptive feeding, and free drinking water was provided during the period. The mice were randomly divided into five groups, namely the control group, the experimental group (IDA group, Fe group, Fe+ live bacteria group and Fe+ postbiotic group), with 8 mice in each group. Among them, the control group was fed with iron-sufficient feed (iron-containing 45mg / kg feed) according to the ANI standard throughout the experiment. The experimental group was fed with a low-iron feed (iron-containing 10mg / kg feed) for four weeks to induce iron deficiency anemia, and then the experiment was terminated after 5 weeks of intervention feeding.

[0068] Intervention method: The control group and IDA group were gavaged with 0.2 mL of normal saline every day, and the experimental group was gavaged with 0.2 mL of ferrous sulfate solution (containing 2 mg / kg body weight of iron); live Akkermansia muciniphila (containing 2×10 8 CFU) + ferrous sulfate solution (containing 2 mg / kg body weight) 0.2 mL; Akkermansia muciniphila postbiotics (2×10 8 TFU) + 0.2 mL of ferrous sulfate solution (containing 2 mg / kg body weight of iron).

[0069] The mice were fasted for 16 h before blood collection at the end of the experiment. 250 μL of blood was collected from the orbital vein and centrifuged at 3000 g for 15 min to separate the serum. The iron content and inflammatory factors in the mouse serum are shown in Figure 4 and Figure 5 .

[0070] Depend on Figure 4It can be seen that compared with the control group, the serum iron content of the IDA group decreased. After iron supplementation, namely the Fe group, the serum iron content recovered, and the difference was significant, but it was still inferior to the control group. After gavage with live Akkermansia muciniphila and postbiotics at the same time, the serum iron content was equivalent to that of the control group, and the difference was not significant. This shows that live Akkermansia muciniphila and postbiotics can effectively promote iron absorption.

[0071] Depend on Figure 5 It can be seen that compared with the IDA group, after supplementing Fe, the inflammatory factors TNF-α and IL-6 in the serum were significantly reduced. After supplementing with live Akkermansia muciniphila or its postbiotics, the inflammatory factors TNF-α and IL-6 decreased even further, close to the level of the control group. This shows that Akkermansia muciniphila and its postbiotics can relieve the level of inflammation while promoting iron absorption.

[0072] Detection method:

[0073] Iron Assay (Abcam, Shanghai) was used to detect the iron content in serum according to the instructions.

[0074] ELISA kits (Sangon Biotechnology, Shanghai) were used to detect the inflammatory cytokines in serum: tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) according to the instructions.

[0075] Example 5 Effect of Akkermansia muciniphila on GLP-1 production in NCI-H716

[0076] GLP-1 secretion was detected using NCI-H716 (human colorectal adenocarcinoma cell) cell model. Cells were cultured in DEME medium supplemented with 10% (v / v) fetal bovine serum and 1% penicillin-streptomycin in a humidified incubator at 37°C and 5% CO2 for serial passages.

[0077] On the day of the experiment, cells were plated at 3 × 10 5 Cells were seeded in collagen-coated 96-well plates at a concentration of 10 cells / mL and cultured overnight. The cells were then starved for 2 hours in HBSS buffer containing 0.2% BSA and then treated for 2 hours according to different experimental groups. The cell supernatant was then collected for measuring GLP-1 concentration.

[0078] The treatment was divided into three groups, namely the blank group (no treatment), the experimental group, and the live bacteria and postbiotics of Akkermansia muciniphila (AKK), Lactobacillus rhamnosus (LR), Lactobacillus casei (LC), and Lactobacillus salivarius (LS). The amount of live bacteria and postbiotics added in each group was the same as in Example 1. The GLP-1 test results are shown in Figure 6As can be seen from the figure, the blank group almost does not secrete GLP-1, while the GLP-1 content of the experimental group treated with live Akkermansia muciniphila or postbiotics is much higher than that of the blank group and other experimental groups, indicating that live Akkermansia muciniphila AKK86 and its postbiotics can promote the secretion of GLP-1.

[0079] The GLP-1 concentration of each sample was determined using a human GLP-1 ELISA kit according to the manufacturer's instructions (Elabscience, Wuhan, China).

[0080] Example 6 Effects of Akkermansia muciniphila and its postbiotics on plasma GLP-1 in mice

[0081] Thirty-two 6-week-old C57BL / 6J male mice were randomly divided into 4 groups after one week of adaptive feeding, with 8 mice in each group. They were control group, high-fat and high-sugar diet (HFD) group, HFD+live bacteria group and HFD+postbiotic group. Dark and light were alternated every 12 hours, and the ambient temperature was 22±1℃.

[0082] Intervention method: The control group was fed with ordinary feed and gavaged with 0.2 mL of normal saline every day. The HFD group was fed with high-fat and high-sugar feed and gavaged with 0.2 mL of normal saline every day. The HFD+live bacteria group was fed with high-fat and high-sugar feed and gavaged with 0.2 mL of bacterial suspension (containing 2×10 live Akkermansia muciniphila) every day. 8 The HFD+postbiotic group was fed a high-fat and high-sugar diet and gavaged with 0.2 mL of bacterial suspension (containing 2×10 postbiotics of Akkermansia muciniphila) every day. 8 TFU). Body weight was measured once a week during the feeding period.

[0083] After 14 weeks of feeding, the mice were fasted overnight and blood was collected and killed by cervical dislocation. The blood glucose and GLP-1 levels in the plasma were tested. The test results are shown in Figure 7 and Figure 8 . As can be seen from the figure, the fasting blood glucose of the HFD+live bacteria group and the HFD+postbiotic group was much lower than that of the HFD group, indicating that supplementing with live Akkermansia muciniphila or its postbiotics can lower blood glucose. In addition, the plasma GLP-1 content of the HFD+live bacteria group and the HFD+postbiotic group was much higher than that of the HFD group, and there was no significant difference with the control group, indicating that supplementing with live Akkermansia muciniphila or its postbiotics can promote the secretion of GLP-1 in the intestine.

[0084] The above examples are for the purpose of illustrating the embodiments disclosed by the present invention and are not to be construed as limiting the present invention. In addition, the various modifications listed herein and the variations of the methods in the invention are obvious to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been specifically described in conjunction with various specific preferred embodiments of the present invention, it should be understood that the present invention should not be limited to these specific embodiments. In fact, various modifications as described above that are obvious to those skilled in the art to obtain the invention should be included within the scope of the present invention.

Claims

1. An Akkermansia muciniphila AKK-86 strain, with a deposit number of CCTCC NO: M 20241304.

2. The Akkermansia muciniphila AKK-86 strain according to claim 1, characterized in that The Akkermansia muciniphila AKK-86 can promote the absorption of iron.

3. A bacterial agent, characterized in that: The bacterial agent comprises the live bacteria of Akkermansia muciniphila AKK-86 and / or its postbiotics as described in claim 1 or 2.

4. The bacterial agent according to claim 3, characterized in that The bacterial agent includes 2*10 8 Live Akkermansia muciniphila AKK-86 bacteria and / or an equivalent amount of postbiotics thereof at cfu / mL or above cfu / g.

5. Use of Akkermansia muciniphila or its postbiotics in the preparation of products promoting iron absorption, iron supplement products, blood sugar lowering products, diabetes prevention products, diabetes treatment products, weight loss products or products for improving intestinal inflammation.

6. The use according to claim 5, characterized in that The Akkermansia muciniphila is the Akkermansia muciniphila AKK-86 according to claim 1 or 2.

7. The use according to claim 6, characterized in that The blood sugar lowering product, diabetes prevention product, diabetes treatment product or weight loss product exerts its effect by promoting the intestinal cells to produce GLP-1 through the Akkermansia muciniphila AKK-86.

8. An iron supplement product, characterized in that: The iron supplement product comprises an iron supplement and Akkermansia muciniphila or its postbiotics.

9. The iron supplement product according to claim 8, characterized in that: The iron supplement is selected from any one or more of the following: ferrous sulfate, sodium ethylenediaminetetraferric, bisglycinate ferrous chelate, dextran iron, ferrous fumarate, polysaccharide iron complex, ferrous succinate.

10. The iron supplement product according to claim 8, characterized in that: The Akkermansia muciniphila is the Akkermansia muciniphila AKK-86 according to claim 1 or 2.

Images